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ABSTRACT 
 
Unmodified reperfusion therapy for acute myocardial infarction (AMI) is associated with 
irreversible myocardial injury beyond that sustained during ischemia. Studies in 
experimental models of ischemia/reperfusion and in humans undergoing reperfusion 
therapy for AMI have examined potential beneficial effects of nitric oxide (NO) supplemented 
at the time of reperfusion. Using a rigorous systematic search approach, we have identified 
and critically evaluated all the relevant experimental and clinical literature to assess whether 
exogenous NO given at reperfusion can limit infarct size. 
An inclusive search strategy was undertaken to identify all in vivo experimental animal and 
clinical human studies published in the period 1990 to 2014 where NO gas, nitrite, nitrate or 
NO donors were given to ameliorate reperfusion injury. Articles were screened at title and 
subsequently at abstract level, followed by objective full text analysis using a critical 
appraisal tool. In twenty-one animal studies, all NO treatments except nitroglycerin afforded 
protection against measures of reperfusion injury, including infarct size, creatinine kinase 
release, neutrophil accumulation and cardiac dysfunction. In three human AMI RCT’s, there 
was no consistent evidence of infarct limitation associated with NO treatment as an adjunct 
to reperfusion. 
Despite experimental evidence that most NO treatments can reduce infarct size when given 
as adjuncts to reperfusion, the value of these interventions in clinical AMI is unproven. Our 
study raises issues for the design of further clinical studies and emphasises the need for 
improved design of animal studies to reflect more accurately the comorbidities and other 
confounding factors seen in clinical AMI. 
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Introduction 
 
Early management of acute myocardial infarction (AMI) focuses on achieving rapid 
reperfusion of the ischemic risk zone in order to minimise irreversible tissue injury. [65] 
Although early reperfusion is undoubtedly beneficial after AMI, it can be associated with 
patterns of reperfusion injury. The deleterious effects of reperfusion on the myocardium 
occur as a result of the rapid reintroduction of oxygenated blood into the ischemic tissue. 
There are likely to be multiple underlying mechanisms of reperfusion injury but the most 
studied aspect is the formation of reactive oxygen species (ROS), in particular superoxide 
(O2-) and hydrogen peroxide.[49] These highly reactive species cause oxidative damage to 
the sarcoplasmic reticulum, mitochondria, cell membrane, nuclear DNA and sarcomeric 
proteins, leading to calcium overload of the cardiomyocytes [50] and opening of the 
mitochondrial permeability transition pore (mPTP).[14] Ultimately, unmodified reperfusion is 
associated with cardiomyocyte apoptosis and accelerated necrosis of cells already 
damaged by ischemia. Furthermore, damage to the microvasculature causes a reduction in 
blood flow leading to the “no-reflow phenomenon”.[55] 
 
Nitric oxide (NO) is endogenously produced within myocardium, principally from L-arginine 
under the influence of nitric oxide synthases (NOS). It can also be produced via NOS-
independent mechanisms including the reduction of tissue reservoirs of nitrite (NO2-) or 
nitrate (NO3-) to liberate NO under hypoxic conditions, [6] such as occurs in the ischemic 
myocardium. The production of NO from NO2- has been shown to reduce myocardial injury 
[8, 33] and the reduction of NO2- is thought to be facilitated by molecules including 
deoxymyoglobin [5] and the enzyme xanthine oxidoreductase [66] among others. NO has a 
short half-life in vivo and the conversion of NOS derived NO into a variety of storage forms 
by oxidase enzymes [57] is an important reservoir of NO. 
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NO has been shown in many experimental studies to modulate ischemia/reperfusion injury. 
Administration of NOS inhibitors has been reported to exacerbate myocardial necrosis [23] 
supporting the notion that endogenous NO is protective against ischemia/reperfusion 
injury.[18] In experimental studies, endogenous NO has been shown to contribute in the 
protective pathways activated in classical and delayed ischemic preconditioning [10] and 
also hibernation [19]. These potential protective effects of endogenous NO have given rise 
to a multitude of experimental and clinical studies focusing on the delivery of exogenous 
NO, in the form of various NO species and NO-donor compounds, to limit 
ischemia/reperfusion injury[7] with the general hypothesis being that NO ameliorates 
ischemia/reperfusion injury. 
 
The current study addresses the question of whether NO treatments/ namely gaseous NO, 
NO2-, NO3- or organic NO donor compounds, as adjuncts to reperfusion following ischemia, 
provide consistent cardioprotection against reperfusion injury, when assessed primarily as 
a reduction in infarct size. We addressed this question by undertaking a systematic 
qualitative review of experimental and clinical studies that have investigated the effects of 
NO treatments, when given specifically in a manner that could modify reperfusion injury in 
(a) in vivo animal models of ischemia/reperfusion or (b) in patients undergoing reperfusion 
therapy for AMI. We identified articles against predefined, highly selective inclusion criteria 
and critically analysed relevant articles to evaluate the quality of the studies. Those studies 
subjected to full text analysis were then synthesised to form the basis of this review.  
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METHODS 
 
Study design 
The study design was based on the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) 27-point guidance[36] together with review protocols published 
by the Cochrane Collaboration.[1] A systematic methodological approach was designed in 
order to reduce reviewer bias when selecting articles for inclusion and to appraise the 
included articles against predefined inclusion criteria to create an objective synthesis of the 
current published data. 
 
Search strategy 
Following a pilot study to scope the approximate period and scale of the relevant scientific 
literature, search terms were agreed by all reviewers (BRJ, GRC, JSB, GFB). Terms were 
expanded with Boolean operators, as well as adjacency and tree techniques, in order to 
combine search terms and narrow the specific literature to be included. Due to differences 
in search functionality between the databases some search terms were adapted or omitted 
for individual databases. Two reviewers (BRJ, GRC) used the final agreed search terms to 
search the Cochrane library, Medline, Embase, Web of Science, and the clinical trials 
databases CT.gov. The strategy was limited exclusively to exogenous sources of NO and 
their specific effects on myocardial reperfusion injury; as such, terms relating to precursors 
such as L-arginine and endogenous NO, or pre-ischemic treatment were excluded. 
 
Eligibility criteria 
We included all animal and human studies utilising exogenous administration of gaseous 
NO, organic NO-donors, NO2-, NO3- or OONO- during periods relevant to reperfusion injury. 
Original articles in the serial literature published in English during the period January 1st 
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1985 to August 15th 2014 were included. Review articles were screened to identify relevant 
publications once the articles reached the full text level of the screening process. We did not 
search university dissertation or thesis repositories. Published outputs were included if they 
met the criteria listed in Table 1. 
 
A critical appraisal tool was developed to allow a comprehensive qualitative critique of the 
articles at full text level (Table 2). 
 
Article selection and data extraction 
Article screening was undertaken in a standardised, non-blinded manner by the two primary 
reviewers (BRJ, GRC) who independently screened the search results for relevance by 
reviewing the titles (11,539) and subsequently the abstracts (548) of the identified studies 
using the eligibility criteria. Following relevance screening, the two reviewers compared 
results to identify any disagreements or queries and the secondary reviewers (JSB, GFB) 
gave input until a consensus was reached. All articles deemed relevant (58 animal studies 
and 35 human studies) underwent full text critical analysis independently by BRJ and GRC 
who concluded which articles were appropriate for inclusion (Table 3). Each of the articles 
was then discussed between the primary reviewers and any disagreements were resolved 
by the secondary reviewers (JSB, GFB). The finalised included and excluded articles were 
then sampled by the secondary reviewers (JSB, GFB) to confirm the consistency of the data 
analysis process. Once the sampling process had been completed, the included studies (21 
animal and 3 human) were critiqued. 
 
Meta-analysis 
A random effects model was used as it was considered that heterogeneity would be 
demonstrated due to varying treatments and animal models. Data are reported as mean 
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difference. Authors were contacted to clarify data values if SEM or SD were not published. 
Statistical heterogeneity was determined using I2. Sub analysis of grouped studies (by 
species, NO donor (data not shown)) did not cause significant deviation from the mean 
difference reported here.  
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RESULTS 
 
Study inclusion/exclusion 
The results of the article selection and data extraction process are summarised in Figure 
1.The database search provided a total of 24,969 citations (from both animal and human 
studies), and after removing duplicate reports, 11,539 remained of which 10,991 were 
discarded at title level, leaving 548 articles. Of these, 463 studies were excluded at abstract 
level since they did not meet the eligibility criteria (Table 1). The remaining 50 animal studies 
and 35 clinical studies were obtained in full text and an additional 8 animal studies were 
identified from the reference lists (“snowballing”) of the remaining animal studies. A total of 
58 animal and 35 human studies were therefore appraised at full text level (See Figure 1). 
Following this appraisal, 37 animal and 32 human studies were not deemed to have 
appropriate methodology or quality for inclusion, leaving 21 animal and 3 human studies to 
be included in the two arms of the review (Table 3). 
  
Characteristics of experimental animal studies 
Table 4 summarises the characteristics and outcomes of 21 in vivo animal studies analysed. 
Animal studies examined the role of NO treatments in anesthetised animals subjected to 
ischemia/reperfusion with infarct size assessment as a major endpoint. The species used 
were cat, dog, mouse, rat, rabbit and pig. In the majority of studies, myocardial ischemia 
was induced by reversible ligation of the left anterior descending coronary artery (or similar 
in rodents). A few studies used alternative methods for induction of ischemia including 
clamping of the aorta, electrically-induced ventricular fibrillation or inflation of a balloon in 
the coronary artery. Duration of ischemia ranged from 30 to 120 minutes with reperfusion 
lasting between 2 and 24 hours. Injury was assessed by infarct size determination, 
predominantly by TTC contrast staining. 
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Six studies administered inhaled NO (iNO), six administered sodium nitrite (NaNO2), five 
administered novel organic NO donors, two administered ONOO-, one administered sodium 
nitroprusside (SNP) and one administered nitroglycerin (NTG). Routes of administration of 
these agents included inhaled, intravenous and intraventricular administration, with timings 
of administration ranging from time points during ischemia but before reperfusion, to 10 
seconds after the point of reperfusion. The concentration of NO treatments varied according 
to which agent was used (e.g. iNO 20-80 ppm, NaNO2 2.4 nmol-12.5 mmol kg/hr, ONOO- 
0.2-20 µM). 
 
Meta-analysis of all experimental studies suggests that infarct size was limited compared to 
relative controls (mean difference of -17.93% [95% confidence interval: -22.05, -13.81]) 
(Figure 2) except when NTG was administered. Sensitivity analysis demonstrated that 
grouping of publications to animal model or specific NOx had little effect on the outcome of 
the analysis (data not shown). Statistical heterogeneity was high in all sub-group analysis, 
yet the mean difference in effect size was consistently similar.  
 
Characteristics of human clinical studies 
The characteristics and outcomes of the three clinical studies which met the criteria for 
analysis are summarised in Table 5. The earlier studies by Hildebrandt et al.[21] and 
Morris et al.[37] administered isosorbide dinitrate over 24-48 h whilst in the most recent 
NIAMI study[59] NaNO2 was administered as a bolus. Reperfusion therapy in the earlier 
studies was carried out by thrombolysis in contrast to the NIAMI trial in which patients 
received PPCI 5 min after sodium nitrite. There was no reduction in infarct size in human 
studies following NOx administration.  
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DISCUSSION 
 
Experimental animal studies 
The key finding of the 21 in vivo animal studies critically reviewed is that, with the exception 
of NTG, NO treatment prior to or during the early reperfusion period can limit infarct size. 
However, considerable heterogeneity of effect was observed, related to both treatment 
(agent, dose, regimen) and species (notably whether collateralised or not). 
 
Our analysis of the combined effects of all animal studies used a random-effects model and 
was reported as mean difference. Although random-effects models typically provide larger 
confidence intervals, the assumption made here was that studies were heterogeneous but 
effects followed some distribution. Indeed the analytical approach here provides an answer 
to the question “what is the average intervention effect?” The large degree of statistical 
heterogeneity is likely due to the differences in animal model and NO treatment utilised. 
However for the purposes of this review, in which we are interested in the overall picture, a 
summary effect of all interventions provides meaningful insight into targeting NO signalling 
in I/R. 
 
Sydnonimine nitric oxide donors 
Two sydnonimine NO donors, C87-3754 and SIN-1, produced a marked reduction in infarct 
size compared to both conventional controls and non-NO donating analogues [29, 60] 
suggesting that protection is afforded by NO, when administered at relatively low doses 
(1mg/kg/h IV). However both studies were conducted in cats, a species with a collateralised 
coronary circulation.[34] Collateralisation does not completely prevent infarction, but may 
alter processes during early ischemia[15] so modifying infarct size. Conversion of 
sydnonimines to release NO is sensitive to low pH, conditions found during early 
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reperfusion.[54] Their use in contemporary studies is limited and haemodynamic profile in 
I/R unreported, however treatment exhibits a reduction in endothelial dysfunction, likely 
caused by NO quenching of free radical species.[60] 
 
Inhaled gaseous NO 
iNO significantly reduced infarct size at concentrations ranging from 40 to 80 ppm [16, 32, 
38-40, 56] as well as decreasing creatine kinase (CK) concentrations and rate of apoptosis 
of cardiomyocytes [32] which was seen even when iNO was administered during short 
periods (e.g. 5 minutes prior to reperfusion).[39] However beneficial effects were not seen 
when iNO was administered immediately before reperfusion. Therefore it is possible 
bioactive carriers of NO, such as nitrite [12] and S-nitrosylated [62] proteins, provide 
protective effects rather than molecular NO itself. Indeed the mechanism by which iNO is 
converted to a more stable nitrogen oxide molecule before entering the blood stream and 
eliciting extra-pulmonary effects remains to be fully elucidated.[41] The suitability of inhaled 
NO as an adjunct to reperfusion in the clinic is therefore questionable. 
 
Nitrite 
NO2- was shown to exert a dose dependent infarct-limiting effect, which peaked at 48 nmol 
when administered intraventricularly, providing significant reduction in infarct size compared 
to control.[8] However, the control treatment used in this study was NO3-, which was 
previously shown to exert a beneficial effect at high doses.[27] A contemporary study by the 
same group using similar timings of reperfusion showed comparable infarct size for a vehicle 
control group, suggesting that NO3- at a concentration of 48 nmol had no cardioprotective 
effect over control. These results are corroborated by a more recent study by Hendgen-Cotta 
et al. who further demonstrated that 48 nmol NaNO2- could limit infarct size in mice.[17] 
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When NO2- was co-administered with an NO scavenger, cardioprotection was abolished, 
suggesting the beneficial effects are NOS independent but NO-dependent.[8] However, 
despite studies showing NO2- to be beneficial, when administered at the point of reperfusion 
it exerted no significant effect on infarct size when administered immediately after 
reperfusion [2] yet LV function after AMI was preserved.[64] This may be due to a difference 
in timing of administration, or possibly due to differences between rodents and dogs; the 
latter have a variably collateralised coronary circulation. Another possible interpretation may 
be the time for the nitrite species to be converted into a cytoprotective nitrogen oxide species 
if the mechanism of cyoprotection is not mediated by s-nitrosylation (For a comprehensive 
review of nitrite mediated protection the reader is directed to Rassaf et al. 2014).[52] 
Acidified NaNO2 and NO in solution have also been demonstrated to limit infarct size in 
feline models of LAD occlusion.[25, 26]  
 
Peroxynitrite 
ONOO- is formed when NO reacts with O2-[35] and shows protective effects when 
administered at low micromolar concentrations while increasing infarct size at higher 
concentrations.[43] Maximal physiological concentrations have been previously 
documented in the order of 2-5 µM.[44, 45] A significant reduction in infarct size was 
observed when ONOO- was administered via intraventricular infusion. However when 
infused intravenously no cardioprotection was afforded[45], suggesting ONOO- acts locally 
rather than systemically. Furthermore, the short half-life and immediate interaction with 
plasma proteins such as glutathione would suggest that intravenous injection would fail to 
elicit the same response. Production of S-nitrosothiols from ONOO- to from more stable 
nitrogen oxide resevoirs is a possible mechanism for affording cytoprotection.[43] The 
generation of ONOO- during early reperfusion from ROS and NO and further ROS induced 
ROS release suggest that ONOO- may not be suitable as a therapeutic agent. 
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Other nitric oxide donor compounds 
Several studies have suggested that novel NO donors may have advantages, such as 
increased potency and reduced tolerance compared to traditional NO donors.[3, 31] 
However whether this is of relevance to the setting of ischemia/reperfusion is unclear, as 
generally agents are not administered over long periods of time. Nevertheless all studies 
using other donors showed a significant reduction in infarct size.[29-31, 47, 60] There were 
however discrepancies in the results with respect to neutrophil accumulation and activation: 
this was seen in all the other NO donor studies , except the work by Siegfried et al.[60], and 
the animal model used (feline or canine) is a potentially confounding factor. Lefer et al.[29, 
30] diverted coronary collateral blood flow away from the ischaemic area by inserting an 
open cannula through the arteriotomy distal to the occluded LAD and therefore suggested 
that the protective effect occurred independently of collateral blood flow. However other 
studies that utilised feline myocardial models failed to measure collateral flow and so it is 
difficult to conclude whether this would have contributed to infarct limitation at reperfusion. 
It may therefore be more appropriate to consider these agents with respect to a more 
representative animal model, such as pig in the future. 
 
Traditional nitric oxide donating compounds 
In two studies, NTG did not reduce infarct size when administered at reperfusion [32, 53] 
which may be due to tolerance induced through continuous infusion or due to a relative 
reduction in its bioavailability.[32] There is sustained contradiction as to precisely how NTG 
causes vasodilation via NO signalling i.e cGMP or nitrosylation. At clinical plasma 
concentrations evidence suggests that free NO is not released [46], but possibly a 
mechanism by which NTG nitrosylates other proteins which may lead to its vasoactive 
actions, a similar mechanism to that proposed for NTG tolerance following chronic 
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administration.[61] Interestingly, NTG could afford late preconditioning in conscious rabbits, 
an observation that was sustained in NO tolerant rabbits.[22] 
 
Downstream targets 
These data support the overriding thesis that NOx is a successful candidate for targeting 
the injurious effects of ischaemia reperfusion injury in animal models. Evidence that 
suggests that endogenous production and maintenance of cofactors of NOS are 
compromised during injury, and the consequential reduction in NO bioavailability further 
supports this rationale. Addition of both L-arganine and tetrahydrobiopterin just prior to 
reperfusion in both rats and swine limit infarct size.[63] Increased NO availability and the 
subsequent reduction in superoxide production provides favourable conditions. Arginase 
inhibition has similarly been shown to limit infarct size by increased NO production.[13] 
Modification of the electron transport chain by S-nitrosation has also been well documented 
as a means of cytoprotection, ultimately inhibiting mitochondrial transition pore opening and 
reducing cyctochrome-c release.[17, 58] The reduction in pH and hypoxic environment 
during ischaemia favours nitrite reduction providing an environment suitable for NO2- to 
afford infarct limitation by targeting complex I. Furthemore, NO has been shown to regulate 
the respiratory complexes and improve myocardial oxygen consumption.[4] Cyclophilin D 
can be S-nitrosylated at Cys203 which results in a reduction in mPTP opening in mouse 
fibroblasts, which is critical in reducing cell death.[42] 
 
Human clinical trials 
Three high quality clinical studies which met the criteria for inclusion were identified. The 
primary endpoint in all three studies was infarct size; there was no evidence of infarct size 
reduction in patients treated with NO compounds immediately prior to reperfusion. There 
was a considerable period of time between the earliest study in 1992 and the most recent 
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study in 2014. Measurement of infarct size in each of the studies was performed in a 
different way. Enzyme release into plasma was used in the earlier studies to measure CK-
MB or hydroxybutyrate dehydrogenase [21, 37] whilst cardiac magnetic resonance (CMR) 
was used in the 2014 NIAMI trial.[59] Unlike the experimental setting where infarct size 
measurement is reliably measured by post mortem histological staining and direct imaging 
techniques, there is as yet no consistent, gold standard technique for assessing infarct 
size relative to risk zone size in the clinical setting.[20] 
 
A reperfusion protocol formed part of the inclusion criteria in this review. However both 
Hildebrandt et al.[21] and Morris et al. [37] performed subgroup analysis on patients in 
which thrombolysis was ineffective or reperfusion was limited. Hildebrandt et al. [21] 
reported in this sub group of patients that isosorbide dinitrate did afford some infarct 
limitation. Morris et al. [37] however, suggest that in their sub-group analysis of patients 
with incomplete reperfusion, judged by ST segment resolution, isosorbide dinitrate had no 
effect on infarct size. They further reported that patients with an intermediate ST elevation 
benefited from isosorbide dinitrate in contrast to patients with large ST elevation in which 
isosorbide dinitrate was deleterious. Siddiqi et al. [59] reported that infarct size in their 
patients was relatively large compared to placebo treated patients in a remote conditioning 
study from 2010, yet there was no relationship between patients with smaller or larger 
infarcts, varying risk areas or chest pain duration. 
 
All clinical studies were conducted double-blind. In all studies patient populations were 
heterogeneous, with similar mean ages and sex distribution. In each of these studies, 
infarct size, time to reperfusion, age, and the presence of comorbidities was variable. This 
is a criticism of translational science generally, which may in part explain the disparity 
between clinical and animal studies. The animal studies included in this review reported 
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data from healthy juvenile animals with no comorbidities and highly regulated infarct size 
and location. The clinical trials reviewed here, like most others, have a study cohort of 
patients with numerous comorbidities and, as the current clinical studies report, varying 
degrees of infarct size, location and indeed reperfusion success. A recent phase 2 trial 
which was published after our literature screening and analysis, in which 82 patients were 
randomized to sodium nitrite or placebo just prior to PPCI reflected the outcomes of the 
human trials included in this review. No reduction in infarct size was observed, measured 
by CK and troponin and subsequent CMR. However a reduction in major adverse cardiac 
events was reported.[28] 
 
The complexity and number of comorbidities that present alongside AMI create significant 
challenges when translating therapies to the clinic. Disruption to cytoprotecitve signalling 
as a consequence of metabolic disturbances and other pathological processes have 
commanded much interest due to unsuccessful translation of cardioprotection strategies. 
Indeed, of particular interest to NOx signalling is the downstream sGC associated kinase 
PKG. The protection afforded by NO donor SNAP was abolished in a hyperlipidaemic rat 
model, via possible oxidative dimerization of PKG in rats fed a cholesterol rich diet.[11] 
Similarly, diabetes has been shown to impair pharmacological postconditioning in an in 
vivo rabbit model. Isoflurane induced infarct size limitation was abrogated in 
hyperglycaemic rabbits, which was associated with impaired Akt/eNOS signalling.[51] 
 
Concomitant pharmacotherapy with pharmacological agents such as antihypertensives, 
anti-anginal drugs, lipid-lowering drugs, anti-platelet aspirin, and drugs used for the 
treatment of diabetes among others, modify the signalling cascades that are of interest to 
limit the injurious effects of AMI and may also confound clinical studies. For example, 
statins have been extensively studied in both animal models and in humans. Although 
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there is a large body of evidence that suggests that many statins positively modify NO 
signalling via eNOS induction (comprehensively reviewed in [48]), pravastatin 
demonstrated opposing effects on myocardial NO levels.[24] Many of these therapies may 
provide protection against irreversible injury and so additional intervention will only induce 
small incremental limitation of infarct size.[9] At high micromolar and millimolar 
concentrations NO can promote cellular injury, a situation that is possible in patients being 
treated with polypharmacy. Therefore it is essential to define the optimum compound, 
formulation and dose to minimise toxicity of these compounds when administered in 
clinical AMI. Timing and administration route are also crucial considerations which may be 
possible when mechanisms are further understood.  
 
Conclusion 
All NO donor agents except NTG exhibit the potential to limit infarct size when given as 
adjuncts to reperfusion in various in vivo animal models of ischemia/reperfusion. Despite 
this there is no definitive conclusion to the exact mechanism(s) by which beneficial effects 
are obtained. The evidence reported in this review emphasises a disparity between 
preclinical animal studies and the human trials. It is clear that the preclinical models included 
for review here, do not reflect the complexities and heterogeneity of the human cohort. The 
lack of standardised infarct size measurement relative to risk zone, marked variation in time 
to reperfusion/intervention and variation in the ischemic territory all present challenges to 
assessment of adjunct therapies. Further well designed pre-clinical models which better 
reflect the complexities of the human setting and subsequent high quality RCTs are needed.  
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FIGURE LEGENDS 
 
Figure 1 Results of database searches and appraisal at different stages of the review 
process. 
 
Figure 2 Infarct size in animal models in groups treated with NOx adjuncts compared to 
control experiments. N.B. NTG treatment for Liu et al. 2007 not reported as no separate 
control group. 


Criteria for inclusion of published animal studies 
a. peer reviewed original article;  
b. in vivo animal study;  
c. conducted on suitable animal species with characterised levels of collateralisation of the 
coronary circulation (rodents, rabbits, pig, cats, and dogs); 
d. documented period of ischemia; 
e. documented period of reperfusion; 
f. intervention group in which animals were administered a documented NO treatment 
(regardless of route of administration) within the latter stages of the ischaemic phase or 
in the early reperfusion phase; 
g. clearly defined contemporary control group where animals received defined control 
treatment; 
h. infarct size measured as endpoint by clearly documented method. 
Criteria for inclusion of published human studies 
a. peer reviewed original article; 
b. documented period of myocardial ischemia (time from onset of chest pain); 
c. documented method of reperfusion; 
d. intervention group in which patients were administered documented NO treatment 
(regardless of route of administration) prior to, or during PCI/thrombolysis; 
e. completed randomised control trial with infarct size estimation as clearly defined 
endpoint. 
 
Critical appraisal tool 
a) details about study population including numbers in each treatment group and baseline 
characteristics; 
b) details regarding intervention and control arms of the study; 
c) specific endpoints being reported and how they were assessed; 
d) whether randomisation of study participants took place; 
e) timing of administration of the intervention being investigated; 
f) reporting of study protocols such as methods and timings of ischemia and reperfusion; 
g) assessment of sample size and power of study; 
h) whether inclusion/exclusion criteria for study or its participants were stated; 
i) whether methods of data analysis used were appropriate for data types being reported; 
j) whether reporting of results was accurate and conclusion of study reflected results reported; 
k) whether limitations of study or conflicts of interest were acknowledged by authors. 
 
Exclusion of articles 
Reasoning No. articles 
Excluded during relevance screening (title plus abstract) level 11,539 
Total no. of articles appraised at full text level 93 
Excluded during full manuscript review: 
 Inappropriate timing of NO donor administration 
 Inadequate/lack of suitable control arm 
 No clear period of ischaemia and/or reperfusion stated 
 NO donation not primary mechanism of action being investigated 
 Ex vivo/in vitro study 
 Inappropriate outcomes measured 
 Not myocardial I/R injury 
 Abstract or preliminary results 
 Review article 
 Foreign language article 
No. of studies excluded at full text level 
 
24 
1 
12 
8 
4 
11 
3 
4 
1 
1 
69 
No. of studies included after full text evaluation 24 
Summary of included experimental studies 
 
Author 
Year 
Animal 
Species 
Exp. Protocol / Primary 
Endpoint determination 
NO donor Timing of NO 
administration 
n (Tx): n 
(control) 
Effect of NO donor on outcome vs control 
Lefer et al., 
1993 
Adult male 
cats 
LAD occlusion 90 min 
Reperfusion 270 min 
Endpoint: IS - TTC 
Tx: Novel sydnonimine 
NO donor C87-3754 
(1mg/kg/h) 
Control: non-NO donating 
analogue C88-3934 
IV infusion 
10 min before 
reperfusion until 
end of experiment 
6:6  ↓ % IS/AAR compared to control (12% vs 33%) 
Hataishi et 
al., 2006 
2-4 month old 
wild type 
mice 
LCA occlusion a.30min, b. 
60 min, c. 120 min 
Reperfusion 24 h 
Endpoint: IS - TTC 
Tx : iNO 80ppm 
Control: inhalation of O2 
(0ppm N2) 
Mechanical ventilator 
20 min before 
reperfusion until 
end of experiment 
a. 13:14 
b. 6:7 
c. 9:11 
 iNO 80ppm ↓ IS/AAR % after 30, 60 and 120 
mins ischaemia 
 iNO dose-response 40/80ppm = ↓IS/AAR % but 
not 20ppm iNO 
Duranksi et 
al., 2005 
Mice 8-10 
week old 
LCA occlusion 30 min 
Reperfusion 24 h 
Endpoint: IS - TTC 
Tx: 
a. NaNO2 48nmol 
b. NaNO2: 2.4, 4.8, 960 
and 1,920nmol 
Control: 48nmol NaNO3 
Intraventricular 
Admin into LV 
cavity 5min prior to 
reperfusion  
a = 8 
b = 6 per 
dose 
Control = 
11 
 All NO2- doses (except 1,920nmol) = significant 
↓ IS/AAR% compared with control 
 48nmol nitrite significantly (P<0.001) reduced IS 
compared to control 
Hendgen –
Cotta et al. 
2008 
Mice 14±3 
week old 
LCA occlusion 30 min 
Reperfusion 24 h 
Endpoint: IS -TTC 
Tx:  
NaNO2 48nmol 
Control: 48nmol NaNO3 
Intraventricular  
Admin into LV 
cavity 5min prior to 
reperfusion 
7:7  48nmol nitrite significantly (P<0.01) reduced IS 
compared to control 
Johnson et 
al., 1990a 
Adult male 
cats 
LAD occlusion 1.5 h 
Reperfusion 4.5 h 
Endpoint: IS - TTC 
Tx = Acidified NaNO2 in 
0.12 M HCl at pH 2.0 
a. 50mmol/kg/h 
b. 25mmol/kg/h 
c. 12.5mmol/kg/h 
Control: acid vehicle 
IV infusion 
30 min after 
induction of 
ischaemia until end 
of reperfusion 
Sham:7 
Control = 
6 
a = 7 
b = 6 
c = 6 
 a = maximal cardioprotection 
 Inf. rates of <12.5mmol/kg/h provide NS 
protection 
 IS/AAR significantly ↓ in NaNO2 (a+b+c) 
compared to vehicle treated groups, 
Baker et al., 
2007 
Male rats 8 
weeks old 
LCA occlusion 30 min 
Reperfusion 2 h 
Endpoint: IS - TTC 
Tx: NaNO2 4mg/kg IV at 
time of admin until end of 
reperfusion phase 
Control: saline 
IV infusion 
a. NO2- 15 min 
after ischaemia 
b. NO2- 10 secs 
after 
reperfusion 
Control = 
6 
a = 6 
b = 6 
 NaNO2 admin in (a) produced significant ↓ 
IS/AAR compared to control 
 NaNO2 admin in (b) shows no significant ↓ in IS 
Johnson et 
al., 
1990 
Adult male 
cats 
LAD occlusion 1.5 h 
Reperfusion 4.5 h 
Tx: acidified NaNO2 (pH 
2.0) – 12.5mmol/kg/h 
Control: acid vehicle  
30 min post-
occlusion until end 
of reperfusion 
6:6  Significant ↓ IS in Tx group compared to control 
Author 
Year 
Animal 
Species 
Exp. Protocol / Primary 
Endpoint determination 
NO donor Timing of NO 
administration 
n (Tx): n 
(control) 
Effect of NO donor on outcome vs control 
Endpoint: IS – TTC, serum 
CK levels 
IV infusion 
Lefer et al., 
1993b 
Dogs (M/F) LAD occlusion 60 min 
Reperfusion 270 min 
Endpoint: IS - TTC 
Tx: Novel cysteine 
containing  mononitrate 
NO donor (SPM-5185) 
Control: NO deficient 
analogue (SPM-5267) 
IV infusion 
After 60 min of 
ischaemia, IV 
infusion to achieve 
plasma conc of 
500nM 
6:5  Highly significant ↓ IS/AAR % in Tx group 
(14.5%) compared to control (47.5%) 
Tripathi et al., 
1997 
Adult male 
mongrel dogs 
LAD occlusion 90 min 
Reperfusion 4 h 
Endpoint: IS – TTC, VF – 
ECG 
Control: Saline 
reperfused 
Tx: acidified NaNO2 
infusion 0.30 Mol/L HCl 
pH 2 
IV infusion 
Saline or NaNO2 
infused at time of 
reperfusion for 4 h 
10:10  NS diff in NaNO2 vs saline Tx groups in % IS/AAR 
or LV 
Liu et al., 
2007 
Juvenile pigs 
(M/F) 
Balloon-mounted stent 
for 50 min 
Reperfusion 240 min 
Endpoint: IS - TTC 
Tx: iNO: 80ppm 
Tx: IV-NTG: 2µg/kg/min 
Control: IV saline 
IV infusion 
10 min before 
reperfusion until 
end of experiment 
Saline = 
14 
iNO = 12 
IV-NTG = 
11 
 IV-NTG did not significantly ↓ IS/AAR compared 
to control 
 iNO ↓ IS by 47% compared to control 
Lefer et al., 
1993a 
Canines (M/F) LAD occlusion 60 min 
Reperfusion 270 min 
Endpoint: IS - TTC 
 
Tx: novel cysteine 
containing  mononitrate 
NO donor (SPM-5185) 
Control: saline 
IV infusion 
60 min of ischaemia 
throughout 
reperfusion 
10:7  ↓ IS in Tx group (SPM5185 = 3.1%, control= 
13.6%) 
Nossuli et al., 
1997 
Adult male 
cats 
LAD occlusion 90 min 
Reperfusion 4.5 h 
Endpoint: IS - TTC 
ONOO- 1µmol/L in pH8.4 
saline as Tx group 
Control = pH8.4 saline 
Intra-ventricular or IV 
infusion 
10 min prior to 
reperfusion until 
end of experiment 
6:6  Significant ↓ in IS/AAR (P<0.001) and 
necrosis/LV (P<0.02) in Tx group compared to 
control 
Shinbo et al., 
2013 
10 week old 
male mice 
LCA occlusion 60 min 
Reperfusion 24 h 
Endpoint: IS - TTC 
Tx: iNO 80ppm gas 
Control:FiO2 0.3 
Inhaled via mechanical 
ventilator 
5 min prior to 
reperfusion until 
end of experiment 
5:5  IS/AAR significantly ↓ in iNO mice compared to 
control 
Nagasaka et 
al., 2008 
Male mice  LCA occlusion 60 min 
Reperfusion 24 h 
Endpoint: IS - TTC 
Tx; iNO 80ppm 
Control: mice breathing 
O2  
iNO administered 
during ischaemia 
a) 9:10 
b) 8:9 
c) 6:7 
 a = ↓ IS/AAR by 32% compared to O2 mice 
(P<0.05) 
Author 
Year 
Animal 
Species 
Exp. Protocol / Primary 
Endpoint determination 
NO donor Timing of NO 
administration 
n (Tx): n 
(control) 
Effect of NO donor on outcome vs control 
Inhaled via mechanical 
ventilator 
for (before 
reperfusion): 
a) 60 min 
b) 5 min 
c) 0.5 min 
 b = ↓ IS/AAR by 31% compared to O2 mice 
(P<0.05) 
Nagasaka et 
al., 2011 
WT mice 8-12 
week old 
 
Mice with 
sGCα1-/- 
deficiency 
LCA occlusion 60 min 
Reperfusion 24 h 
Endpoint: IS - TTC 
Tx: iNO 80ppm 
Control: O2 inhalation 
Inhaled via mechanical 
ventilator 
60 min beginning 
10 min after LCA 
occlusion until 10 
min reperfusion 
WT = 
10:12 
sGCα1-/- = 
10:10 
 iNO Tx in WT mice caused 41% ↓ in MI/AAR 
(P<0.001), however did not alter MI/AAR in 
sGCα1-/- mice 
Pabla et al., 
1995 
Mongrel dogs 
(M/F) 
LAD occlusion 90 min 
Reperfusion 270 min 
Endpoint: IS - TTC 
 
Tx: Long acting NO donor: 
CAS-1609 IV bolus 
1.25mg, followed by 
infusion of 1mg/h 
Control: normal saline 
bolus and infusion 
IV infusion 
Bolus 10 min before 
reperfusion 
followed by infusion 
for reperfusion 
period 
7:7  IS/AAR in Tx group = 8%, control = 29% (P<0.01) 
(70% ↓ in necrosis) 
Salloum et 
al., 2007 
Male NZ 
white rabbits 
LCA occlusion 30 min 
Reperfusion 3 h 
Endpoint: IS - TTC 
Tx: NTG 2µg/kg/min IV via 
continuous infusion 
Control: 0.9% saline  
IV infusion 
5 min prior to 
reperfusion 
continuing for 65 
min 
7:6  NS diff in IS/AAR between NTG and saline 
groups (31.5% vs 33.8% respectively) 
Nossuli et al., 
1998 
Adult male 
cats 
LAD occlusion 90 min 
Reperfusion 270 min 
Endpoint: IS - TTC 
Tx : ONOO- infusion in 
pH8.4 saline at: 
a) 0.2µM 
b) 2µM 
c) 20µM 
Control=pH8.4 saline 
Route: IV infusion 
Intraventricular 
infusion admin 
10nmin prior to 
reperfusion and 
maintained 
throughout 
reperfusion 
Control=6 
a) = 6 
b) = 7 
c) = 6 
 Only 2µM dose of ONOO- significantly ↓ 
IS/AAR% - 14.4% in Tx compared to 30.3% 
control P<0.01) 
Neye et al., 
2012 
Male Rats LCA occlusion 120 min 
Reperfusion 3 h 
Endpoint: IS - TTC 
Tx: iNO 50ppm 
Control: room air 
Inhaled via mechanical 
ventilator  
a) iNO/control 
admin 
throughout 3h 
reperfusion  
b) iNO/control 
admin 
throughout 5h 
8:8  a = IS/ LV ↓ in iNO compared to control 
however IS/AAR was NS 
 b = IS/LV was significantly ↓ compared to 
control and group a. 
Author 
Year 
Animal 
Species 
Exp. Protocol / Primary 
Endpoint determination 
NO donor Timing of NO 
administration 
n (Tx): n 
(control) 
Effect of NO donor on outcome vs control 
period of I and 
R  
Siegfried et 
al., 1992 
Adult male 
mongrel cats 
LAD occlusion 90 min 
Reperfusion 270 min 
Endpoint: IS - TTC 
a = NO donor: SIN-1 
b = NO donor:C87-3754 
c = Inactive NO donor: 
C88-3934 
d = Control: 0.9% saline 
Bolus 1mg/kg followed by 
1mg/kg/h infusion IV 
Administered into 
jugular vein 10min 
prior to reperfusion 
until end of 
reperfusion period 
a) = 8 
b) = 6 
c) =6 
d) =6 
 a = ↓ IS/AAR from 29% to 9% (P<0.001) 
 b = ↓ IS/AAR from 31% to 11% (P<0.001) 
Johnson et 
al., 1991 
Adult male 
cats 
LAD occlusion 90 min 
Reperfusion 270 min 
Endpoints: IS - TTC 
a = NO in solution 
b = vehicle 
1.1 mL/kg/h IV 
30 min after LAD 
ligation until end of 
reperfusion period 
a) = 6 
b) = 6 
 a = ↓ IS/AAR from 26 % to 7 % (P<0.01) 
 
LAD = left anterior descending coronary artery; LV = left ventricle; AAR = area at risk; MI = myocardial infarction; PPM = parts per million; IS = infarct size; CK = creatinine kinase; NTG = nitroglycerin; HR = heart rate; 
BP = blood pressure; NaNO2 = sodium nitrite; NaNO3 = sodium nitrate; ONOO- = peroxynitrite; PRI = pressure rate index; TTC = triphenyltetrazolium chloride; NO2- = nitrite; NO = nitric oxide; HCl = hydrochloric acid; 
SNP = sodium nitroprusside; LCA = left coronary artery; ROS = reactive oxygen species; iNO = inhaled nitric oxide; LVSP = left ventricular systolic pressure; NS = not significant; cGMP = 3’, 5’-cyclic guanosine 
monophosphate; VF = ventricular fibrillation 
 
Summary of included clinical studies 
Author 
Year 
NO donor (dose, route, 
duration) 
Time from 
onset of 
chest pain 
to 
admission 
Reperfusion 
technique 
Infarct size 
determination 
n (Tx): n 
(control) 
Effect of NO donor on 
outcome vs control 
Hildebrandt 
et al., 1992 
Isosorbide dinitrate 
1.0-10.0 mg/mL 
Infusion for 48 h 
≤ 8h Thrombolysis 
with 
streptokinase 
CK-MB every 
4 hours for 72 
h 
50:49 No reduction in infarct size 
when reperfusion confirmed 
Morris et al., 
1995 
Isosorbide dinitrate 
1.0-6.0 mg/h 
Infusion for 24 h 
minimum 
≤ 24h Thrombolysis αHBDH blood 
samples every 
12 h on days 1 
& 2 and daily 
on days 3, 4, 
& 5. 
150:151 No reduction in infarct size, 
ventricular remodelling or ST 
segment resolution at day 3. 
Siddiqi et al., 
2014 
Sodium nitrite 
70 μmol 
Infusion for 5 min 
≤ 12h PPCI CMR % LV 
mass 6-8 days 
post infarct. 
118:111 No reduction in infarct size 
or secondary endpoints 
including ejection fraction 
and troponin 1. 
